ONESOURCE

By Rishika Sadam

June 12 (Reuters) - Indian contract drug manufacturer OneSource Specialty Pharma ONEO.NS expects strong growth in its order book over the next three years, driven by the global boom in weight-loss drugs, its top executive said on Monday.

Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster injectable obesity drugs from Denmark's Novo Nordisk NOVOb.CO and U.S.-based Eli Lilly LLY.N. The active chemical compound in Novo's injectable Wegovy drug, semaglutide, will go off patent in 2026 in a few markets, including India.

OneSource, which added 15 orders related to obesity and diabetes drugs in fiscal year 2025, said there are more in the pipeline. The global obesity market is estimated to be valued at $150 billion by the early 2030s.

The company develops and manufactures complex biological drugs, vials, injectables, and soft gelatin capsules for larger pharmaceutical firms.

"Our growth over the next few years will be driven by commercial launches of GLP-1s (weight-loss and diabetes drugs) by our global customers in all the key markets opening post patent expiry in 2026," CEO Neeraj Sharma told Reuters in an interview.

Backed by increasing demand from weight-loss drug manufacturers, OneSource's order book across all service verticals should expand in line with 30% compound annual growth rate through fiscal year 2028, according to the CEO.

OneSource, which competes with larger players such as Piramal Pharma PIRM.NS and Divi's DIVI.NS in contract research, development and manufacturing, is investing about $100 million to expand its drug device facilities, the CEO said.

The company, which was demerged from Strides Pharma Science SRID.NS and listed in January, is also looking at setting up a global footprint in manufacturing, both in Europe and the U.S.

(Reporting by Rishika Sadam; Editing by Mrigank Dhaniwala)

(([email protected];))

May 5 (Reuters) - Onesource Specialty Pharma Ltd ONEO.NS:

• APPROVES CONSOLIDATION OF SINGAPORE BUSINESS OPERATIONS

• MARCH-QUARTER CONSOL PROFIT 985 MILLION RUPEES

• MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 4.26 BILLION RUPEES

Source text: ID:nBSEbRgFgV

Further company coverage: ONEO.NS

(([email protected];;))

April 10 (Reuters) - Onesource Specialty Pharma Ltd ONEO.NS:

• ONESOURCE SPECIALTY PHARMA LTD - UNIT 2 GRANTED GMP CERTIFICATION BY ANVISA

• ONESOURCE SPECIALTY PHARMA LTD - CERTIFICATION FOLLOWS SUCCESSFUL REGULATORY INSPECTION IN NOVEMBER 2024

• ONESOURCE SPECIALTY PHARMA LTD - APPROVAL ENABLES SUPPLY OF DDCS AND GLP-1S TO BRAZILIAN MARKET

Source text: ID:nBSE2XzrqQ

Further company coverage: ONEO.NS

(([email protected];))

March 13 (Reuters) - Onesource Specialty Pharma Ltd ONEO.NS:

• ONESOURCE SPECIALTY PHARMA LTD - RECEIVES TAX ADJUSTMENT ORDER OF 425.95 MILLION RUPEES

Source text: ID:nBSE2yYjCG

Further company coverage: ONEO.NS

(([email protected];;))

Jan 29 (Reuters) - Onesource Specialty Pharma Ltd ONEO.NS:

• ONESOURCE SPECIALTY PHARMA DEC-QUARTER CONSOL LOSS 688.5 MILLION RUPEES

• ONESOURCE SPECIALTY PHARMA DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 3.93 BILLION RUPEES

Source text: ID:nBSE60thVs

Further company coverage: ONEO.NS

(([email protected];))